{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:35:50Z","timestamp":1783632950530,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,12,4]],"date-time":"2013-12-04T00:00:00Z","timestamp":1386115200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s12032-013-0792-4","type":"journal-article","created":{"date-parts":[[2013,12,3]],"date-time":"2013-12-03T05:50:30Z","timestamp":1386049830000},"source":"Crossref","is-referenced-by-count":19,"title":["Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors"],"prefix":"10.1007","volume":"31","author":[{"given":"Masatomo","family":"Nishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,4]]},"reference":[{"issue":"27","key":"792_CR1","first-page":"66","volume":"18","author":"A Fasolo","year":"2012","unstructured":"Fasolo A, Sessa C. Targeting mTOR pathways in human malignancies. Curr Pharm Des. 2012;18(27):66\u201377.","journal-title":"Curr Pharm Des."},{"key":"792_CR2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1615\/CritRevOncog.v17.i1.60","volume":"17","author":"K Sheppard","year":"2012","unstructured":"Sheppard K, Kinross KM, Solomon B, Pearson RB, Phillips WA. Targeting PI3 kinase\/AKT\/mTOR signaling in cancer. Crit Rev Oncog. 2012;17:69\u201395.","journal-title":"Crit Rev Oncog."},{"key":"792_CR3","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157488411797189433","volume":"6","author":"HD Husseinzadeh","year":"2011","unstructured":"Husseinzadeh HD, Garcia JA. Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma. Curr Clin Pharmacol. 2011;6:214\u201321.","journal-title":"Curr Clin Pharmacol."},{"key":"792_CR4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449\u201356.","journal-title":"Lancet."},{"key":"792_CR5","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271\u201381.","journal-title":"N Engl J Med."},{"key":"792_CR6","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","volume":"13","author":"G Fyfe","year":"1995","unstructured":"Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688\u201396.","journal-title":"J Clin Oncol."},{"key":"792_CR7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.20.1.289","volume":"20","author":"RJ Motzer","year":"2002","unstructured":"Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289\u201396.","journal-title":"J Clin Oncol."},{"key":"792_CR8","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.juro.2006.09.073","volume":"177","author":"T Kurahashi","year":"2007","unstructured":"Kurahashi T, Miyake H, Hara I, Fujisawa M. Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. J Urol. 2007;177:757\u201361.","journal-title":"J Urol."},{"key":"792_CR9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/cncr.25402","volume":"117","author":"T Abou Youssif","year":"2011","unstructured":"Abou Youssif T, Fahmy MA, Koumakpayi IH, et al. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer. 2011;117:290\u2013300.","journal-title":"Cancer."},{"key":"792_CR10","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1158\/1078-0432.CCR-04-0112","volume":"10","author":"X Zhou","year":"2004","unstructured":"Zhou X, Tan M, Stone Hawthorne V, et al. Activation of the Akt\/mammalian target of rapamycin\/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res. 2004;10:6779\u201388.","journal-title":"Clin Cancer Res."},{"key":"792_CR11","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1464-410X.2009.08538.x","volume":"104","author":"B Dai","year":"2012","unstructured":"Dai B, Kong YY, Ye DW, Ma CG, Zhou X, Yao XD. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int. 2012;104:1009\u201316.","journal-title":"BJU Int."},{"key":"792_CR12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/CCO.0b013e32835fc857","volume":"25","author":"EA Singer","year":"2013","unstructured":"Singer EA, Gupta GN, Marchalik D, Slinivasan R. Evolving therapeutic targets in renal cell carcinoma. Curr Opin Oncol. 2013;25:273\u201380.","journal-title":"Curr Opin Oncol."},{"key":"792_CR13","doi-asserted-by":"crossref","first-page":"594","DOI":"10.4161\/cc.11.3.19096","volume":"11","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Zheng XF. mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle. 2012;11:594\u2013603.","journal-title":"Cell Cycle."},{"key":"792_CR14","doi-asserted-by":"crossref","unstructured":"Ducker GS, Atreya CE, Simko JP, et al. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 2013. doi: 10.1038\/onc.2013.92 .","DOI":"10.1038\/onc.2013.92"},{"key":"792_CR15","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.4161\/cc.10.22.18124","volume":"10","author":"P Yellen","year":"2011","unstructured":"Yellen P, Saqcena M, Salloum D, et al. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle. 2011;10:3948\u201356.","journal-title":"Cell Cycle."},{"key":"792_CR16","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1158\/1078-0432.CCR-11-3137","volume":"18","author":"CK Lee","year":"2012","unstructured":"Lee CK, Marschner IC, Simes RJ, et al. Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clin Cancer Res. 2012;18:3188\u201396.","journal-title":"Clin Cancer Res."},{"key":"792_CR17","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1002\/cncr.24438","volume":"115","author":"RA Figlin","year":"2009","unstructured":"Figlin RA, de Souza P, McDermott D, et al. Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer. 2009;115:3651\u201360.","journal-title":"Cancer."},{"key":"792_CR18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11523-011-0172-y","volume":"6","author":"SK Pal","year":"2011","unstructured":"Pal SK, Figlin RA. Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma. Target Oncol. 2011;6:5\u201316.","journal-title":"Target Oncol."},{"key":"792_CR19","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.1158\/0008-5472.CAN-07-0881","volume":"67","author":"G Armengol","year":"2007","unstructured":"Armengol G, Rojo F, Castellv\u0131 J, et al. 4E-binding protein 1: a key molecular \u2018\u2018funnel factor\u2019\u2019 in human cancer with clinical implications. Cancer Res. 2007;67:7551\u20135.","journal-title":"Cancer Res."},{"key":"792_CR20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ccr.2010.05.023","volume":"18","author":"QB She","year":"2010","unstructured":"She QB, Halilovic E, Ye Q, et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell. 2010;18:39\u201351.","journal-title":"Cancer Cell."},{"issue":"13","key":"792_CR21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1472-6890-13-3","volume":"1","author":"SA Aziz","year":"2013","unstructured":"Aziz SA, Sznol JA, Adeniran A, et al. Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors. BMC Clin Pathol. 2013;1(13):3.","journal-title":"BMC Clin Pathol."}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-013-0792-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-013-0792-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-013-0792-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T07:03:18Z","timestamp":1597129398000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-013-0792-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,4]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["792"],"URL":"https:\/\/doi.org\/10.1007\/s12032-013-0792-4","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,4]]},"article-number":"792"}}